Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery

Anita Chvatal, Rita Ambrus, Petra Party, Gábor Katona, Orsolya Jójárt-Laczkovich, P. Szabó-Révész, Elias Fattal, Nicolas Tsapis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large size (>5 µm) and low density (<0.2 mg/cm3) formulations. With the appropriate amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8%, while the emitted fraction (EF) reached 85.4%, both higher than for the non-porous particles. Stability tests demonstrated that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the first time large porous particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are reported.

Original languageEnglish
Pages (from-to)68-75
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume559
DOIs
Publication statusPublished - Mar 25 2019

Fingerprint

meloxicam
Lung
Pharmaceutical Preparations
Cystic Fibrosis
Powders
Chronic Obstructive Pulmonary Disease
Anti-Inflammatory Agents
Inflammation

Keywords

  • Andersen cascade impactor
  • Dry powder inhalation
  • Large porous particles
  • Meloxicam
  • Spray drying

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. / Chvatal, Anita; Ambrus, Rita; Party, Petra; Katona, Gábor; Jójárt-Laczkovich, Orsolya; Szabó-Révész, P.; Fattal, Elias; Tsapis, Nicolas.

In: International Journal of Pharmaceutics, Vol. 559, 25.03.2019, p. 68-75.

Research output: Contribution to journalArticle

Chvatal, Anita ; Ambrus, Rita ; Party, Petra ; Katona, Gábor ; Jójárt-Laczkovich, Orsolya ; Szabó-Révész, P. ; Fattal, Elias ; Tsapis, Nicolas. / Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. In: International Journal of Pharmaceutics. 2019 ; Vol. 559. pp. 68-75.
@article{76949be4207348198b7a328e42fba23c,
title = "Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery",
abstract = "Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large size (>5 µm) and low density (<0.2 mg/cm3) formulations. With the appropriate amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8{\%}, while the emitted fraction (EF) reached 85.4{\%}, both higher than for the non-porous particles. Stability tests demonstrated that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the first time large porous particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are reported.",
keywords = "Andersen cascade impactor, Dry powder inhalation, Large porous particles, Meloxicam, Spray drying",
author = "Anita Chvatal and Rita Ambrus and Petra Party and G{\'a}bor Katona and Orsolya J{\'o}j{\'a}rt-Laczkovich and P. Szab{\'o}-R{\'e}v{\'e}sz and Elias Fattal and Nicolas Tsapis",
year = "2019",
month = "3",
day = "25",
doi = "10.1016/j.ijpharm.2019.01.034",
language = "English",
volume = "559",
pages = "68--75",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery

AU - Chvatal, Anita

AU - Ambrus, Rita

AU - Party, Petra

AU - Katona, Gábor

AU - Jójárt-Laczkovich, Orsolya

AU - Szabó-Révész, P.

AU - Fattal, Elias

AU - Tsapis, Nicolas

PY - 2019/3/25

Y1 - 2019/3/25

N2 - Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large size (>5 µm) and low density (<0.2 mg/cm3) formulations. With the appropriate amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8%, while the emitted fraction (EF) reached 85.4%, both higher than for the non-porous particles. Stability tests demonstrated that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the first time large porous particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are reported.

AB - Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, from meloxicam aqueous solution with pH adjustment. A comparison study between non-porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the aimed large size (>5 µm) and low density (<0.2 mg/cm3) formulations. With the appropriate amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8%, while the emitted fraction (EF) reached 85.4%, both higher than for the non-porous particles. Stability tests demonstrated that, after 10 weeks of storage, no significant difference could be detected in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the first time large porous particles, with enhanced aerodynamic properties, from an aqueous solution of meloxicam are reported.

KW - Andersen cascade impactor

KW - Dry powder inhalation

KW - Large porous particles

KW - Meloxicam

KW - Spray drying

UR - http://www.scopus.com/inward/record.url?scp=85060609184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060609184&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.01.034

DO - 10.1016/j.ijpharm.2019.01.034

M3 - Article

VL - 559

SP - 68

EP - 75

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -